Key result
Drug-coated balloons are an established therapy for in-stent restenosis and native small-vessel disease, with ongoing investigation for acute myocardial infarction, chronic total occlusion, and bifurcations.
Why the study?
While drug-coated balloons have established roles in in-stent restenosis and native small-vessel disease, their applications in settings such as acute myocardial infarction, chronic total occlusion, and bifurcation lesions remain under investigation.
Drug-coated balloons are an established therapy for in-stent restenosis and small-vessel disease, with expanding indications in complex coronary interventions and high-risk patients.
No takes yet. Share an insight, caveat, or question.
Supports established DCB use in ISR and small-vessel disease; leaves open expansion to AMI, CTO, and bifurcations.
Buccheri et al. (2019) conducted a review in Coronary Artery Disease. Drug-coated balloons (DCBs) was evaluated. Drug-coated balloons are an established therapy for in-stent restenosis and native small-vessel disease, with ongoing investigation for acute myocardial infarction, chronic total occlusion, and bifurcations.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: